Alleviating Trunk Low Back Pain, With an Active Medical Device Study (ATLAS)
NCT ID: NCT03801941
Last Updated: 2022-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2019-04-01
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is an intervention al non blinded study with a crossover design comparing pain evaluated with an Analogue Visual Scale with and without the ATLAS device during 5 standardized daily activities.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessing the Japet.W+ Lumbar Traction Device in Rehabilitation for Patients With Non-specific Mechanical Low Back Pain
NCT06718348
Assessing the Impact of the Axomove Therapy Medical Device on Low Back Pain Patients
NCT05910463
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
NCT07195422
Feasibility of a One-day-and-a-half for Patients With Low Back Pain
NCT04133818
Effects of a Lower Back Wrap Device on Lower Back Pain, Physical Function, and Quality of Life
NCT06749912
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Population: patients with chronic low back pain admitted for a 4 weeks rehabilitation program.
Intervention: active rehabilitation and wearing the ATLAS device 60 min per day. The ATLAS study is carried out during the 5 first days of the rehabilitation program.
Primary outcome: Pain intensity evaluation with a 100 mm Visual Analogue Scale (VAS) during 5 standardized activities (the most intensive pain during the 5 activities is recorded), with and without wearing the ATLAS device.
Secondary outcome measures: percentage of patients reporting pain decrease of at least 20 mm on the 100 mm VAS during the 5 standardized activities with the ATLAs device compared without wearing the device. Percentage of relieved patients (percentage of patient reporting pain intensity less than 30 mm on the 100 mm VAS with wearing the device). Pain intensity evaluated with the 100 mm VAS before and after 60 min of wearing the ATLAS device.
Randomization: two groups (i.e. group A and B). Primary outcome is evaluated at day 4 and 5, with a crossover design (Group A: pain is evaluated during activities with the device at day 4 and without the device at day 5. Group B: pain is evaluated during activities without the device at day 4 and with the device at day 5).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with the ATLAS Device at the 4th day and without the device at the 5th day of a 4 weeks rehabilitation program.
wearing ATLAS device during evaluation at 4th day
Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
wearing ATLAS device during evaluation at 5th day
Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
Group B
Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without the ATLAS Device at the 4th day and with the device at the 5th day of a 4 weeks rehabilitation program.
wearing ATLAS device during evaluation at 4th day
Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
wearing ATLAS device during evaluation at 5th day
Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
wearing ATLAS device during evaluation at 4th day
Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
wearing ATLAS device during evaluation at 5th day
Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Analogical visual scale superior or egal to 3/10
* BMI \< 30
* 18 \< Age \< 75 years
* Patients who signed the informed consent
* Hospital Anxiety and depression score less than 11
Exclusion Criteria
* Skin pathology of the trunk region
* Antecedent of surgery of spinal fusion
* Implanted neurostimulation treatment
* Scoliosis with Cobb angle \> 30°
* History of vertebral fracture
* BMI \> 30
* Respiratory failure
* Recent rib fracture (less than 3 month)
* Pregnancy or breastfeeding
* Osteoporosis
* Refusal to participate to the study
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Japet Medical Devices
INDUSTRY
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vincent Tiffreau, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Swynghedau, CHU
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-A01729-46
Identifier Type: OTHER
Identifier Source: secondary_id
2016_67
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.